Symbiotec Pharmalab Ltd (SYMBIOTEC)
🎯 Key Takeaways
- Symbiotec Pharmalab Ltd operates in the niche pharmaceutical space with a focus on complex generics and contract development, maintaining a conservative capital structure and stable profitability. The company is in a mature phase, characterized by consistent margins and low leverage, with limited growth signals from recent disclosures.
- ⚠️ Revenue stagnation poses a long-term growth risk, especially in a competitive pharmaceutical sector with limited product differentiation.
📖 The Story
Symbiotec Pharmalab Ltd operates in the niche pharmaceutical space with a focus on complex generics and contract development, maintaining a conservative capital structure and stable profitability. The company is in a mature phase, characterized by consistent margins and low leverage, with limited growth signals from recent disclosures.
📰 What's Happening
In September 2026, the company formalized internal disclosure protocols by empowering key managerial personnel to assess materiality under SEBI Regulation 30(5), enhancing governance transparency. This regulatory update reflects improved compliance infrastructure but does not indicate new business initiatives or strategic shifts. No major capital projects, M&A, or capacity expansions were disclosed in recent filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 |
|---|---|
| Revenue | 203 |
| Operating Profit | 47 |
| OPM % | 23.4% |
| Net Profit | 30 |
| EPS | ₹5.47 |
Operating revenue of ₹203 crore in Q1 FY26 reflects stable top-line performance, supported by an operating margin of 23.4% and net profit of ₹30 crore, indicating resilient earnings quality. The slight improvement in profitability occurs amid minimal changes in cost structure, suggesting effective operational discipline despite a stagnant revenue base.
🔮 Management Outlook & What's Next
Management has not provided forward-looking guidance on revenue growth, margin trajectory, or capital allocation in recent filings. The absence of strategic commentary suggests a focus on operational continuity rather than expansion or transformation.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity Capital | 11 | 11 |
| Reserves | 804 | 835 |
| Borrowings | 541 | 523 |
| Total Liabilities | 1,580 | 1,598 |
| Fixed Assets | 402 | 432 |
| Investments | 38 | 1 |
| Total Assets | 1,580 | 1,598 |
The balance sheet remains stable, with equity held at ₹11 crore and reserves growing modestly to ₹835 crore, indicating retained earnings accumulation. Borrowings declined slightly to ₹523 crore from ₹541 crore, reflecting a cautious approach to leverage, while total assets grew marginally, signaling limited reinvestment activity.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +175 |
| Investing | -227 |
| Financing | +36 |
| Net Cash Flow | -16 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Revenue stagnation poses a long-term growth risk, especially in a competitive pharmaceutical sector with limited product differentiation. 2. High reserve concentration relative to equity may indicate limited reinvestment opportunities, potentially constraining future scalability.
🧠 Analyst's Read
Symbiotec Pharmalab exhibits characteristics of a cash-generative, low-growth business with strong margins and conservative leverage. Investors should monitor for signs of strategic reinvestment or market expansion, as current operations appear to be in a maintenance phase without clear catalysts for acceleration.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SYMBIOTEC files new disclosures
Track SYMBIOTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SYMBIOTEC — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd